Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study to test clotting Drug's safety in indian hemophilia patients

NCT ID NCT07446010

Not yet recruiting Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Mar 07, 2026 · Last updated May 18, 2026 · Updated 6 times

Summary

This study looks at how safe and effective Octocog alfa is for treating bleeding episodes in adults with severe hemophilia A in India. It will follow 33 people who have used Factor VIII before and are getting the drug only when they bleed. The goal is to see how the drug works in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • All India Institute Of Medical Sciences

    New Delhi, India

  • Christian Medical College & Hospital

    Ludhiana, India

  • Department of Medicine Assam Medical College & Hospital

    Dibrugarh, India

  • Government of Medical College Kozhikode

    Kozhikode, India

  • Sahyadri Super Speciality Hospital

    Pune, India

  • Sanjay Gandhi Post Graduate Institute & Medical Sciences

    Lucknow, India

Conditions

Explore the condition pages connected to this study.